(Q37714082)

22 August 2017

1 reference

title

Chronic inflammatory demyelinating polyradiculoneuropathy: diagnostic and therapeutic challenges for a treatable condition (English)

1 reference

chronic inflammatory demyelinating polyradiculoneuropathy

22 August 2017

main subject

0 references

0 references

0 references

3

1 reference

22 August 2017

2

Claudia Sommer

2 references

ORCID Public Data File 2021

22 August 2017

Jean-Michel Vallat

1

1 reference

22 August 2017

publication date

1 April 2010

1 reference

22 August 2017

1 reference

22 August 2017

volume

9

1 reference

22 August 2017

issue

4

1 reference

22 August 2017

page(s)

402-412

1 reference

Diagnostic value of nerve biopsy for atypical chronic inflammatory demyelinating polyneuropathy: evaluation of eight cases

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Chronic inflammatory demyelinating polyradiculoneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Recurrent polyneuropathies and their corticosteroid treatment; with five-year observations of a placebo-controlled case treated with corticotrophin, cortisone, and prednisone

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

The electrodiagnostic distinctions between chronic familial and acquired demyelinative neuropathies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Pe

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Proposed revised electrophysiological criteria for chronic inflammatory demyelinating polyradiculoneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Electrodiagnostic criteria for acute and chronic inflammatory demyelinating polyradiculoneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Epidemiologic variability of chronic inflammatory demyelinating polyneuropathy with different diagnostic criteria: study of a UK population

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Evidence-based treatment of chronic immune-mediated neuropathies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Chronic polyneuropathies in Vest-Agder, Norway

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Prevalence and incidence rates of chronic inflammatory demyelinating polyneuropathy in the Japanese population.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Chronic inflammatory demyelinating polyneuropathy--update on pathogenesis, diagnostic criteria and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Sural nerve T-cell receptor Vbeta gene utilization in chronic inflammatory demyelinating polyneuropathy and vasculitic neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

gamma delta T cells infiltrating sensory nerve biopsies from patients with inflammatory neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Serum interleukin-2 concentrations in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy: comparison with other neurological diseases of presumed immunopathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Serum levels of tumor necrosis factor-alpha in chronic inflammatory demyelinating polyneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Expression of chemokines in cerebrospinal fluid and serum of patients with chronic inflammatory demyelinating polyneuropathy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Interleukin-6 levels in the cerebrospinal fluid and serum of patients with Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Expression of endothelial leukocyte adhesion molecule-1 (ELAM-1) in chronic inflammatory demyelinating polyneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Chronic inflammatory demyelinating polyneuropathy: decreased claudin-5 and relocated ZO-1

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Expression of accessory molecules for T-cell activation in peripheral nerve of patients with CIDP and vasculitic neuropathy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Fas-mediated T-cell apoptosis is impaired in patients with chronic inflammatory demyelinating polyneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Impairment of circulating CD4+CD25+ regulatory T cells in patients with chronic inflammatory demyelinating polyradiculoneuropathy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Susceptibility to chronic inflammatory demyelinating polyradiculoneuropathy is associated to polymorphic GA repeat in the SH2D2A gene

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Enhanced B7 costimulatory molecule expression in inflammatory human sural nerve biopsies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Expression of the co-stimulatory molecule BB-1, the ligands CTLA-4 and CD28 and their mRNAs in chronic inflammatory demyelinating polyneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Development of spontaneous autoimmune peripheral polyneuropathy in B7-2-deficient NOD mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Expression of CD28-related costimulatory molecule and its ligand in inflammatory neuropathies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Macrophage clustering as a diagnostic marker in sural nerve biopsies of patients with CIDP

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Chronic inflammatory demyelinating polyneuropathy: immunopathological and ultrastructural study of peripheral nerve biopsy in 42 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Immunoglobulin and Complement Deposits in Nerves of Patients With Chronic Relapsing Polyneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Anti-peripheral myelin antibody in patients with demyelinating neuropathy: quantitative and kinetic determination of serum antibody by complement component 1 fixation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Anti-SGPG antibody in CIDP: nosological position of IgM anti-MAG/SGPG antibody-associated neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

P0 protein is a target antigen in chronic inflammatory demyelinating polyradiculoneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Targeting of myelin protein zero in a spontaneous autoimmune polyneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Humoral and cellular immune responses to myelin protein peptides in chronic inflammatory demyelinating polyradiculoneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Chronic dysimmune demyelinating polyneuropathy: a clinical and electrophysiological study of 93 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Chronic dysimmune neuropathy. A subclassification based upon the clinical features of 102 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Pure motor chronic inflammatory demyelinating polyneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Late motor involvement in cases presenting as "chronic sensory demyelinating polyneuropathy"

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

"Chronic sensory demyelinating neuropathy": chronic inflammatory demyelinating polyneuropathy presenting as a pure sensory neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Fatigue as the main presenting symptom of chronic inflammatory demyelinating polyradiculoneuropathy: a study of 11 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Minimal and asymptomatic chronic inflammatory demyelinating polyneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Multifocal demyelinating neuropathy with persistent conduction block

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Multifocal acquired demyelinating sensory and motor neuropathy: the Lewis-Sumner syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Multifocal motor sensory demyelinating neuropathy: inflammatory demyelinating polyradiculoneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Distal acquired demyelinating symmetric neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Chronic acquired demyelinating symmetric polyneuropathy classified by pattern of weakness

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Chronic immune sensory polyradiculopathy: a possibly treatable sensory ataxia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Multifocal inflammatory demyelinating neuropathy: a distinct clinical entity?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Atypical varieties of chronic inflammatory demyelinating neuropathies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Chronic inflammatory demyelinating polyneuropathy (CIDP) in diabetics

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Chronic inflammatory demyelinating polyneuropathy in diabetics: motor conductions are important in the differential diagnosis with diabetic polyneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Incidence and prevalence of CIDP and the association of diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Cranial magnetic resonance imaging in chronic demyelinating polyneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Evidence for central nervous system demyelination in chronic inflammatory demyelinating polyradiculoneuropathy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Chronic inflammatory demyelinating polyradiculoneuropathy associated with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Coexistent hereditary and inflammatory neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Childhood chronic inflammatory demyelinating neuropathies: clinical course and long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Childhood chronic inflammatory demyelinating polyneuropathy: clinical course and long-term outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Chronic inflammatory demyelinating polyradiculoneuropathy in children: I. Presentation, electrodiagnostic studies, and initial clinical course, with comparison to adults

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Chronic inflammatory demyelinating polyradiculoneuropathy in children: II. Long-term follow-up, with comparison to adults

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Subacute inflammatory demyelinating polyneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Chronic inflammatory demyelinating polyradiculoneuropathy. A clinical and electrophysiological study of 92 cases.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Chronic inflammatory demyelinating polyneuropathy presenting with features of GBS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Patients with chronic inflammatory demyelinating polyneuropathy initially diagnosed as Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Distinguishing acute-onset CIDP from Guillain-Barré syndrome with treatment related fluctuations

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Classifications and treatment responses in chronic immune-mediated demyelinating polyneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Proximal nerve conduction studies in chronic inflammatory demyelinating polyneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Acquired inflammatory demyelinating polyneuropathies: clinical and electrodiagnostic features

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Comparison of electrodiagnostic abnormalities and criteria in a cohort of patients with chronic inflammatory demyelinating polyneuropathy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Clinical spectrum of chronic acquired demyelinating polyneuropathies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Dispersion of the distal compound muscle action potential as a diagnostic criterion for chronic inflammatory demyelinating polyneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Optimizing the use of electrophysiology in the diagnosis of chronic inflammatory demyelinating polyneuropathy: a study of 20 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Derivation and validation of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Validity of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy: a multicentre European study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Axonal CIDP: a premature concept?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Length-dependent weakness and electrophysiological signs of secondary axonal loss in chronic inflammatory demyelinating polyradiculoneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Chronic progressive steroid responsive axonal polyneuropathy: A CIDP variant or a primary axonal disorder?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Utility of somatosensory evoked potentials in chronic acquired demyelinating neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Magnetic resonance imaging of the cauda equina in chronic inflammatory demyelinating polyneuropathy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Spinal root and plexus hypertrophy in chronic inflammatory demyelinating polyneuropathy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Nerve root hypertrophy as the cause of lumbar stenosis in chronic inflammatory demyelinating polyradiculoneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Brachial plexus hypertrophy in chronic inflammatory demyelinating polyradiculoneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Chronic inflammatory demyelinating polyradiculoneuropathy: unusual clinical features and therapeutic responses.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Demonstration of spinal cord and nerve root abnormalities by diffusion neurography

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Cutaneous innervation in chronic inflammatory demyelinating polyneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Unmyelinated fibers in sural nerve biopsies of chronic inflammatory demyelinating polyneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Link between peripheral neuropathy and monoclonal dysglobulinemia: a study of 66 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Efficacy of intravenous immunoglobulin in patients with IgG monoclonal gammopathy and polyneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Polyneuropathy associated with IgG/IgA monoclonal gammopathy: a clinical and electrophysiological study of 15 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

The natural history of chronic demyelinating neuropathy associated with benign IgM paraproteinaemia. A clinical and neurophysiological study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Peripheral neuropathy associated with IgM monoclonal gammopathy: correlations between M-protein antibody activity and clinical/electrophysiological features in 40 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Conduction block in neuropathies with necrotizing vasculitis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Osteosclerotic myeloma and peripheral neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

High-dose therapy and autologous blood stem cell transplantation in POEMS syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Uncompacted myelin lamellae in polyneuropathy, organomegaly, endocrinopathy, M-protein and skin changes syndrome. Ultrastructural study of peripheral nerve biopsy from 22 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Serum VEGF levels in POEMS syndrome and in immune-mediated neuropathies.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Sensory CIDP presenting as cryptogenic sensory polyneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Long-term follow-up of patients with chronic inflammatory demyelinating polyradiculoneuropathy, without and with monoclonal gammopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Pulsed high dose dexamethasone treatment in chronic inflammatory demyelinating polyneuropathy: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Treatment of chronic inflammatory demyelinating polyneuropathy with pulsed oral steroids

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Treatment of dys-immune neuropathies.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

A novel trial design to study the effect of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

High-dose cyclophosphamide without stem-cell rescue for refractory CIDP

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

High-dose cyclophosphamide results in long-term disease remission with restoration of a normal quality of life in patients with severe refractory chronic inflammatory demyelinating polyneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Successful autologous stem cell transplantation in a patient with chronic inflammatory demyelinating polyneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Efficacy of mycophenolate mofetil in patients with chronic immune demyelinating polyneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Mycophenolate mofetil for chronic inflammatory demyelinating polyradiculoneuropathy: An open-label study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Cyclosporin A in resistant chronic inflammatory demyelinating polyradiculoneuropathy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Intractable chronic inflammatory demyelinating polyneuropathy treated successfully with ciclosporin

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Rituximab-responsive CIDP

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Etanercept (Enbrel) therapy for chronic inflammatory demyelinating polyneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Interferon beta-1a as an investigational treatment for CIDP.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Pure motor demyelinating neuropathy: deterioration after steroid treatment and improvement with intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Distribution patterns of demyelination correlate with clinical profiles in chronic inflammatory demyelinating polyneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Onset and course of chronic inflammatory demyelinating polyneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Age of onset influences clinical features of chronic inflammatory demyelinating polyneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

Long term prognosis of chronic inflammatory demyelinating polyneuropathy: a five year follow up of 38 cases.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970041-7

7 January 2021

10.1016/S1474-4422(10)70041-7

Identifiers

DOI

1 reference

22 August 2017

1 reference